Zhang Chi, Yang Chao, Shi Qingming
Department of Oncology, Anhui Chest Hospital, Hefei, 230022, People's Republic of China.
Anhui Medical University Clinical College of Chest, Hefei, 230022, People's Republic of China.
Cancer Manag Res. 2025 Jan 15;17:65-82. doi: 10.2147/CMAR.S495006. eCollection 2025.
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Mutations within the TP53 gene represent critical molecular events in NSCLC, contributing to the tumorigenesis in the pulmonary epithelial tissues. TP53 is a widely researched prognostic indicator in NSCLC, and pathological investigations have revealed a weak to mild negative predictive effect for TP53. Mutated p53 protein may have some pro-oncogenic impact, and the variations may change tumor inhibitors into oncogenes. The diverse mutational spectrum of TP53 in NSCLC with different mutations is linked to varied treatment responses. In contrast, first-line chemotherapeutics to this progress are limited, however, randomized trials with new chemotherapeutics have shown significant survival benefits. This review highlighted the critical influence of TP53 gene mutations on pathological-sensitivity and overall survival outcomes in NSCLC. Further research is needed to explore TP53 mutation-specific pathways and their effects on NSCLC progression and treatment effectiveness.
非小细胞肺癌（NSCLC）是全球癌症相关死亡的主要原因。TP53基因内的突变是NSCLC中的关键分子事件，促成肺上皮组织中的肿瘤发生。TP53是NSCLC中一项经过广泛研究的预后指标，病理研究显示TP53具有弱至中度的阴性预测作用。突变的p53蛋白可能具有一些促癌作用，并且这些变异可能会将肿瘤抑制基因转变为癌基因。NSCLC中TP53具有不同突变的多样突变谱与不同的治疗反应相关。相比之下，针对这一进展的一线化疗药物有限，然而，新化疗药物的随机试验已显示出显著的生存获益。本综述强调了TP53基因突变对NSCLC病理敏感性和总生存结局的关键影响。需要进一步研究来探索TP53突变特异性途径及其对NSCLC进展和治疗效果的影响。
